公开(公告)号：US20230046904A1

公开(公告)日：2023-02-16

申请号：US17761097

申请日：2020-09-17

Applicant: GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

Inventor： Yuguang WANG ,  Feilan WANG ,  Nong ZHANG

IPC: A61K31/198 ,  A61K39/395 ,  A61K45/06

Abstract: The invention provides methods for treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a small molecule inhibitor of the PD-1/PD-L1 interaction or a pharmaceutically acceptable salt or prodrug thereof in combination with a therapeutically effective amount of an anti-PD-1 antibody, wherein the small molecule inhibitor of the PD-1/PD-L1 interaction is not a protein.

公开(公告)号：US20230192653A1

公开(公告)日：2023-06-22

申请号：US17911053

申请日：2021-03-08

Applicant: GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

Inventor： Yuguang WANG ,  Zhenhua FENG ,  Feilan WANG

IPC: C07D401/14 ,  C07K16/28 ,  A61P35/00

CPC classification number: C07D401/14 ,  C07K16/2896 ,  A61P35/00 ,  C07B2200/13

Abstract: The disclosure provides new therapeutic uses for certain fused ring pyrimidine compounds, in particular for treating patients having a cancer which expresses elevated fibroblast growth factor receptor oncogene partner 2 (FGFR1OP2) and/or elevated FGFR1, or expresses a FGFR1-FGFR1OP2 fusion protein, and for treating patients who are being treated with an immune checkpoint inhibitor.

公开(公告)号：US20220313626A1

公开(公告)日：2022-10-06

申请号：US17621576

申请日：2020-06-23

Applicant: GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

Inventor： Yugang WANG ,  Feilan WANG ,  Nong ZHANG

IPC: A61K31/137 ,  A61K31/198 ,  A61K31/357 ,  A61K31/277 ,  A61K31/397 ,  A61K31/401 ,  A61K31/454 ,  A61K31/4196 ,  A61K31/4025 ,  A61K31/423 ,  A61K31/4545 ,  A61P35/02

Abstract: Provided herein are methods for treating a cancer in a subject having a tumor with interstitial fluid pressure (IFP) of at least 10 mmHg, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or prodrug thereof, which is an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1 and which is not a protein, alone, or in combination with other agents, e.g., in combination with the use of anti-PD-1/PD-L1 antibodies, in combination with an inhibitor of the CTLA-4/B7 interaction, or in combination with an inhibitor binding to VEFG.